NCT00423501View on ClinicalTrials.gov

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

PHASE2CompletedINTERVENTIONAL
Enrollment

306

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

Placebo

sc weekly

DRUG

taspoglutide

20mg sc weekly

DRUG

taspoglutide

10mg sc every 2 weeks

DRUG

taspoglutide

5mg sc weekly

DRUG

taspoglutide

10mg sc weekly

DRUG

taspoglutide

20mg sc every 2 weeks

Trial Locations (49)

1002

Riga

1233

Sofia

1606

Sofia

2050

Camperdown

3900

Satu Mare

5000

Adelaide

5800

Pleven

6400

Dimitrovgrad

7002

Rousse

9010

Varna

10115

Berlin

11650

Mexico City

14080

Mexico City

14609

Rochester

14610

Mexico City

20010

Washington D.C.

23249

Richmond

30167

Hanover

30189

Woodstock

37431

Bad Lauterberg im Harz

41460

Neuss

42086

Pachuca

44340

Guadalajara

44650

Guadalajara

51270

Kaunas

55116

Mainz

60607

Chicago

64460

Monterrey

75246

Dallas

78229

San Antonio

79707

Midland

90402

Nuremberg

92304

Klaipėda

97239

Portland

100163

Ploieşti

400006

Cluj-Napoca

500365

Brasov

520064

Jud Covasna

540011

Mures

550245

Sibiu

62704-1433

Springfield

02826

Görlitz

01015

Guatemala City

Unknown

Hong Kong

Bucharest

08661

Vilnius

03100

Mexico City

020475

Bucharest

050452

Bucharest

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00423501 - A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin. | Biotech Hunter | Biotech Hunter